Autopsy report · NCT04649060

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

“The sponsor decided to terminate the study due to financial issues following an FDA request for a partial clinical hold.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 54 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Oncopeptides AB

Sponsor type

Industry

Conditions

Relapsed Multiple Myeloma; Relapsed-Refractory Multiple Myeloma

Interventions

Melflufen; Dexamethasone; Daratumumab

Participants

54

Sites

26

Countries

Bulgaria, Czechia, Georgia, Germany, Greece, Norway, Poland, Russia, Serbia, Spain, Ukraine

Trials that died the same way

• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (84% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (83% match in meaning)
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (83% match in meaning)
• Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
  “The Sponsor chose to terminate this study for commercial reasons.” (82% match in meaning)
• A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
  “The study was terminated by sponsor for reasons of adjusted clinical development strategy.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.